Silence Therapeutics (SLN) Hisse Özeti
Bir biyoteknoloji şirketi olan Silence Therapeutics plc, hematoloji, kardiyovasküler ve nadir hastalıklarda belirli hedef genlerin ekspresyonunu inhibe etmek için kısa girişimli ribonükleik asit (siRNA) içeren yeni moleküllerin keşfi ve geliştirilmesi ile uğraşmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
+ 1 daha fazla risk
SLN Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Silence Therapeutics plc Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$13.17 |
| 52 Haftanın En Yüksek Seviyesi | US$17.58 |
| 52 Haftanın En Düşük Seviyesi | US$4.19 |
| Beta | 1.41 |
| 1 Aylık Değişim | 21.38% |
| 3 Aylık Değişim | 112.42% |
| 1 Yıllık Değişim | 141.21% |
| 3 Yıllık Değişim | 52.96% |
| 5 Yıllık Değişim | -43.96% |
| Halka arzdan bu yana değişim | -32.46% |
Son Haberler & Güncellemeler
Seeking Alpha • Aug 19
Silence Therapeutics: Making Some Recent Noise
Summary Silence Therapeutics have moved higher on recent trial results, and the company also addressed its funding needs. SLN's lead asset, divesiran for polycythemia vera, faces significant competition from Takeda's rusfertide, which is likely to launch in Q4 2026. Analyst firms are currently constructive on the company's prospects. An analysis around Silence Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 12
SLN: Phase 2 Success And Equity Programs Will Drive Upside Potential
Analysts have raised their fair value estimate for Silence Therapeutics from $31.20 to $35.60, citing updated assumptions related to the discount rate, revenue growth, profit margin, and future P/E levels. What’s in the News for Silence Therapeutics Silence Therapeutics reported positive topline results from the Phase 2 SANRECO trial of divesiran in 48 phlebotomy dependent polycythemia vera patients.Recent updates
Seeking Alpha • Aug 19
Silence Therapeutics: Making Some Recent Noise
Summary Silence Therapeutics have moved higher on recent trial results, and the company also addressed its funding needs. SLN's lead asset, divesiran for polycythemia vera, faces significant competition from Takeda's rusfertide, which is likely to launch in Q4 2026. Analyst firms are currently constructive on the company's prospects. An analysis around Silence Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaAnlatı Güncellemesi • Aug 12
SLN: Phase 2 Success And Equity Programs Will Drive Upside Potential
Analysts have raised their fair value estimate for Silence Therapeutics from $31.20 to $35.60, citing updated assumptions related to the discount rate, revenue growth, profit margin, and future P/E levels. What’s in the News for Silence Therapeutics Silence Therapeutics reported positive topline results from the Phase 2 SANRECO trial of divesiran in 48 phlebotomy dependent polycythemia vera patients.Anlatı Güncellemesi • Jun 15
SLN: Upcoming Phase 2 Data And ATM Program Will Shape Upside Potential
Analysts have kept their $31.20 price target for Silence Therapeutics unchanged, with only minor tweaks to inputs such as discount rate, profit margin and forward P/E assumptions informing the latest update. What's in the News Silence Therapeutics presented follow-up and quality-of-life data from the Phase 1 SANRECO study of divesiran in 21 phlebotomy-dependent polycythemia vera patients at the European Hematology Association 2026 Annual Congress, showing fewer required phlebotomies during and after treatment and reported improvements in PV-related symptoms and overall quality of life.Anlatı Güncellemesi • Jun 01
SLN: Future Offering Program Will Shape Upside Risk Reward Profile
Analysts have adjusted their price target on Silence Therapeutics to $31.20. This reflects updated assumptions around growth, profitability and a higher future P/E multiple that together indicate a different risk and reward profile than before.Analiz Makalesi • Feb 05
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive
To the annoyance of some shareholders, Silence Therapeutics plc ( NASDAQ:SLN ) shares are down a considerable 27% in...Analiz Makalesi • Jan 31
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analiz Makalesi • Oct 19
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analiz Makalesi • Sep 28
Pinning Down Silence Therapeutics plc's (NASDAQ:SLN) P/S Is Difficult Right Now
With a median price-to-sales (or "P/S") ratio of close to 9.9x in the Biotechs industry in the United States, you could...Analiz Makalesi • Aug 13
Newsflash: Silence Therapeutics plc (NASDAQ:SLN) Analysts Have Been Trimming Their Revenue Forecasts
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...Analiz Makalesi • Aug 12
Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...Anlatı Güncellemesi • Aug 08
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The upward revision in Silence Therapeutics’ price target reflects significantly improved consensus revenue growth forecasts and a lower future P/E multiple, resulting in an increased fair value estimate from $32.37 to $37.26. What's in the News Silence Therapeutics approved the application of Article 159 of its articles of association, effective from the recent AGM to the next annual general meeting.Analiz Makalesi • May 11
Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The analysts might have been a bit too bullish on Silence Therapeutics plc ( NASDAQ:SLN ), given that the company fell...Analiz Makalesi • May 06
Silence Therapeutics plc's (NASDAQ:SLN) Price Is Right But Growth Is Lacking After Shares Rocket 50%
Those holding Silence Therapeutics plc ( NASDAQ:SLN ) shares would be relieved that the share price has rebounded 50...
Yeni Anlatı • Apr 01
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments.Analiz Makalesi • Mar 22
Silence Therapeutics plc (NASDAQ:SLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Silence Therapeutics plc ( NASDAQ:SLN ) share price has dived 29% in the last...Analiz Makalesi • Mar 06
These Analysts Think Silence Therapeutics plc's (NASDAQ:SLN) Sales Are Under Threat
Market forces rained on the parade of Silence Therapeutics plc ( NASDAQ:SLN ) shareholders today, when the analysts...Analiz Makalesi • Mar 04
We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analiz Makalesi • Jan 28
Risks Still Elevated At These Prices As Silence Therapeutics plc (NASDAQ:SLN) Shares Dive 26%
Unfortunately for some shareholders, the Silence Therapeutics plc ( NASDAQ:SLN ) share price has dived 26% in the last...Analiz Makalesi • Dec 10
Silence Therapeutics plc (NASDAQ:SLN) May Have Run Too Fast Too Soon With Recent 54% Price Plummet
Silence Therapeutics plc ( NASDAQ:SLN ) shareholders that were waiting for something to happen have been dealt a blow...Analiz Makalesi • Oct 04
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio
You may think that with a price-to-sales (or "P/S") ratio of 38.4x Silence Therapeutics plc ( NASDAQ:SLN ) is a stock...Analiz Makalesi • Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Silence Therapeutics plc ( NASDAQ:SLN ) last week released its latest second-quarter, and things did...Analiz Makalesi • Jun 17
Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
You may think that with a price-to-sales (or "P/S") ratio of 26.8x Silence Therapeutics plc ( NASDAQ:SLN ) is a stock...Analiz Makalesi • May 21
Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. By way of example, Silence...Analiz Makalesi • Feb 07
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Silence Therapeutics plc ( NASDAQ:SLN ) shareholders will have a reason to smile today, with the analysts making...Analiz Makalesi • Nov 27
Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Silence Therapeutics plc ( NASDAQ:SLN ) shares have had a really impressive month, gaining 65% after a shaky period...Seeking Alpha • Sep 08
Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
U.K.-based clinical-stage biotech Silence Therapeutics plc (NASDAQ:SLN) announced Thursday that the FDA granted Fast Track Designation to SLN124 as a treatment for polycythemia vera (PV), a type of blood cancer. SLN124, belonging to a drug class called short interfering ribonucleic acid (siRNA) therapeutics, is set to undergo a Phase 1/2 study in PV this year. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling them to reach patients sooner. In a clinical trial last year, SLN124 indicated proof of mechanism and was well tolerated among healthy volunteers.Seeking Alpha • Aug 12
Silence Therapeutics prices 5.95M ADSs at $9.50/share
Silence Therapeutics (NASDAQ:SLN) has priced an underwritten offering of 5.95M American Depositary Shares, each representing three ordinary shares, at a price of $9.50/ADS, for aggregate gross proceeds of ~$56.5M. All of the ADSs are being offered by Silence. Offering is expected to close on or about August 16, 2022. Silence intends to use the net proceeds of the offering, together with its existing cash and cash equivalents to fund the advancement of its clinical trials, including its Phase 2 trial of SLN360 in ASCVD and its Phase 1/2 trial of SLN124 in polycythemia vera, as well as expansion of pipeline programs, working capital and general corporate purposes.Hissedar Getirileri
| SLN | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | -5.7% | 5.2% | -2.1% |
| 1Y | 141.2% | 43.5% | 18.8% |
Getiri vs. Endüstri: SLN geçen yıl % 43.5 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: SLN geçen yıl % 18.8 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| SLN volatility | |
|---|---|
| SLN Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: SLN hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: SLN 'nin haftalık oynaklığı ( 15% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1994 | 88 | Iain Ross | www.silence-therapeutics.com |
Bir biyoteknoloji şirketi olan Silence Therapeutics plc, hematoloji, kardiyovasküler ve nadir hastalıklarda belirli hedef genlerin ekspresyonunu inhibe etmek için kısa girişimli ribonükleik asit (siRNA) içeren yeni moleküllerin keşfi ve geliştirilmesi ile uğraşmaktadır. Şirket, polisitemi vera için Faz 2 geliştirme aşamasında olan Divesiran'ı (SLN124) ve kompleman aracılı böbrek hastalıkları için SLN548'i geliştirmektedir. Ayrıca yüksek lipoprotein(a) ile ilişkili kardiyovasküler hastalıklar için Zerlasiran (SLN360); dislipidemi için SLN312; hiperkolesterolemi için SLN365; ve obezite için SLN098 geliştirmektedir.
Silence Therapeutics plc Temel Bilgiler Özeti
| SLN temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$819.45m |
| Kazançlar(TTM) | -US$59.95m |
| Gelir(TTM) | US$615.00k |
1,289x
P/S Oranı-13.2x
F/K OranıSLN aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| SLN gelir tablosu (TTM) | |
|---|---|
| Gelir | US$615.00k |
| Gelir Maliyeti | US$87.00k |
| Brüt Kâr | US$528.00k |
| Diğer Giderler | US$60.48m |
| Kazançlar | -US$59.95m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.00 |
| Brüt Marj | 85.85% |
| Net Kâr Marjı | -9,748.46% |
| Borç/Özkaynak Oranı | 0% |
SLN uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/20 04:09 |
| Gün Sonu Hisse Fiyatı | 2026/08/20 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Silence Therapeutics plc 14 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Howard Miller | Canaccord Genuity |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Keay Nakae | Chardan Capital Markets, LLC |